Aloxi
palonosetron
Table of contents
Overview
This is a summary of the European public assessment report (EPAR) for Aloxi. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Aloxi.
This EPAR was last updated on 19/07/2018
Authorisation details
Product details | |
---|---|
Name |
Aloxi
|
Agency product number |
EMEA/H/C/000563
|
Active substance |
palonosetron hydrochloride
|
International non-proprietary name (INN) or common name |
palonosetron
|
Therapeutic area (MeSH) |
|
Anatomical therapeutic chemical (ATC) code |
A04AA05
|
Publication details | |
---|---|
Marketing-authorisation holder |
Helsinn Birex Pharmaceuticals Ltd.
|
Revision |
21
|
Date of issue of marketing authorisation valid throughout the European Union |
22/03/2005
|
Contact address |
Product information
26/04/2018 Aloxi - EMEA/H/C/000563 - II/0045/G
Contents
- Annex I - Summary of product characteristics
- Annex IIA - Manufacturing-authorisation holder responsible for batch release
- Annex IIB - Conditions of the marketing authorisation
- Annex IIIA - Labelling
- Annex IIIB - Package leaflet
Please note that the size of the above document can exceed 50 pages.
You are therefore advised to be selective about which sections or pages you wish to print.
Pharmacotherapeutic group
Pharmacotherapeutic group
-
Antiemetics and antinauseants
-
Serotonin (5HT3) antagonists
Therapeutic indication
Therapeutic indication
Aloxi is indicated in adults for:
- the prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy,
- the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy.
Aloxi is indicated in paediatric patients 1 month of age and older for:
- the prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy and prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy.